Literature DB >> 10328537

Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA.

A Giraud1, Y Ataman-Onal, N Battail, N Piga, D Brand, B Mandrand, B Verrier.   

Abstract

The Semliki Forest virus (SFV) vector system is a new approach for in vivo expression of heterologous proteins and can also be used to generate specific immune responses in animal models. HIV-1 envelope glycoprotein produced using the SFV expression system is correctly folded, cleaved, transported to the cell surface and exhibits functional activity. We evaluated a recombinant Semliki Forest virus naked RNA-based immunization protocol for generation of monoclonal antibodies against the HIV-1 envelope glycoprotein. In vitro-transcribed RNA encoding for the SFV replicase complex and Env protein of HIV-1 (HXB2 strain) was injected intramuscularly to mice. This approach elicited an Env-specific antibody response in four mice out of five and a monoclonal antibody, 12H2, directed against gp41 was produced. Our results show that recombinant SFV RNA immunization can potentially be used as a quick and direct method to produce monoclonal antibodies, with the particular advantage that vectored RNA, rather than purified antigen, delivers a complex oligomer produced correctly.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328537     DOI: 10.1016/s0166-0934(99)00009-9

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Development and characterization of a monoclonal antibody against the putative T cells of Labeo rohita.

Authors:  Sanjay C Rebello; Gaurav Rathore; Peyush Punia; Neeraj Sood
Journal:  Cytotechnology       Date:  2015-03-07       Impact factor: 2.058

2.  Self Replicating Gene Vaccine Carrying P1-2A Gene of FMDV Serotype O and its Effects on the Immune Responses of Cattle.

Authors:  G Nagarajan; P Ravikumar; C Ashok Kumar; G R Reddy; H J Dechamma; V V S Suryanarayana
Journal:  Indian J Virol       Date:  2011-05-10

Review 3.  Current progress in innovative engineered antibodies.

Authors:  William R Strohl
Journal:  Protein Cell       Date:  2017-08-18       Impact factor: 14.870

Review 4.  Alphavirus-based vaccines.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2014-06-16       Impact factor: 5.048

Review 5.  Replicon RNA Viral Vectors as Vaccines.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2016-11-07

Review 6.  RNA-based drugs and vaccines.

Authors:  Kenneth Lundstrom
Journal:  Expert Rev Vaccines       Date:  2014-09-14       Impact factor: 5.217

Review 7.  Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2020-11-18       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.